Quick Answer
Organogenesis Holdings Inc. reported Total Revenue of $564.17 million for fiscal year 2025.
Organogenesis Holdings Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $564.17M +17.0% |
$482.04M +11.3% |
$433.14M -3.9% |
$450.89M -3.5% |
$467.36M +38.2% |
$338.30M +29.6% |
| Net Income | $37.03M +4201.0% |
$861.0K -82.6% |
$4.95M -68.2% |
$15.53M -83.5% |
$94.20M +446.6% |
$17.23M +144.5% |
| Diluted EPS | $0.15 +1600.0% |
-$0.01 -125.0% |
$0.04 -66.7% |
$0.12 -82.9% |
$0.70 +366.7% |
$0.15 +135.7% |
| Total Assets | $598.73M +20.3% |
$497.89M +8.2% |
$460.02M +2.4% |
$449.36M +1.4% |
$443.26M +52.7% |
$290.22M +31.5% |
| Cash and Equivalents | $93.68M -30.9% |
$135.57M +30.6% |
$103.84M +1.3% |
$102.48M -10.1% |
$113.93M +35.0% |
$84.39M |
| Stockholders Equity | $300.13M +14.2% |
$262.90M -5.7% |
$278.66M +15.4% |
$241.53M +0.1% |
$241.34M +70.2% |
$141.81M +172.6% |
| R&D Expense | $44.54M -11.4% |
$50.27M +13.3% |
$44.38M +11.6% |
$39.76M +29.3% |
$30.74M +53.1% |
$20.09M +35.7% |
| Operating Income | $44.69M +3583.6% |
-$1.28M -110.2% |
$12.53M -43.8% |
$22.30M -69.1% |
$72.22M +170.5% |
$26.70M +189.4% |
| Gross Profit | — | $366.30M +12.1% |
$326.66M -5.6% |
$345.87M -2.1% |
$353.16M +40.7% |
$250.98M +35.6% |
| Shares Outstanding | 126.95M +1.0% |
125.73M -4.3% |
131.32M +0.3% |
130.92M +1.7% |
128.68M +0.7% |
127.73M +21.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $150.86M | +31.0% | +49.4% |
| Net Income | September 30, 2025 | $21.57M | +74.9% | +329.6% |
| Diluted EPS | September 30, 2025 | $0.11 | +22.2% | +210.0% |
| Total Assets | September 30, 2025 | $509.83M | +14.2% | +10.6% |
| Cash and Equivalents | September 30, 2025 | $63.74M | -32.4% | -12.8% |
| Long-Term Debt | June 30, 2019 | $39.66M | — | +0.1% |
| Stockholders Equity | September 30, 2025 | $255.13M | -8.4% | +9.4% |
| R&D Expense | September 30, 2025 | $13.22M | +27.8% | +27.2% |
| Operating Income | September 30, 2025 | $20.73M | +232.1% | +264.8% |
| Gross Profit | March 31, 2025 | $62.97M | -22.5% | -28.8% |
| Shares Outstanding | September 30, 2025 | 126.91M | -4.3% | +0.0% |
- Organogenesis Holdings Inc. reported Total Revenue of $564.17 million for fiscal year 2025.
- Organogenesis Holdings Inc. showed an increase of +17.0% in Total Revenue compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported Net Income of $37.03 million for fiscal year 2025.
- Organogenesis Holdings Inc. showed an increase of +4201.0% in Net Income compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported Diluted EPS of $0.15 per share for fiscal year 2025.
- Organogenesis Holdings Inc. showed an increase of +1600.0% in Diluted EPS compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported Total Assets of $598.73 million for fiscal year 2025.
- Organogenesis Holdings Inc. showed an increase of +20.3% in Total Assets compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported Cash and Equivalents of $93.68 million for fiscal year 2025.
- Organogenesis Holdings Inc. showed a decrease of -30.9% in Cash and Equivalents compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported Stockholders Equity of $300.13 million for fiscal year 2025.
- Organogenesis Holdings Inc. showed an increase of +14.2% in Stockholders Equity compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported R&D Expense of $44.54 million for fiscal year 2025.
- Organogenesis Holdings Inc. showed a decrease of -11.4% in R&D Expense compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported Operating Income of $44.69 million for fiscal year 2025.
- Organogenesis Holdings Inc. showed an increase of +3583.6% in Operating Income compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported Gross Profit of $366.30 million for fiscal year 2024.
- Organogenesis Holdings Inc. showed an increase of +12.1% in Gross Profit compared to the prior fiscal year.
- Organogenesis Holdings Inc. reported Shares Outstanding of 126.95 million shares for fiscal year 2025.
- Organogenesis Holdings Inc. showed an increase of +1.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: